PANEL DISCUSSION: Value of Clinical Utility
Moderator: Elaine Lyon, Ph.D., Medical Director, Molecular Genetics, ARUP
Panelists to be Announced
History Leading Up to NIPT
Mark I. Evans, M.D., Clinical Professor, Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine, Mount Sinai Hospital
End-User of Prenatal Testing in Clinical Practice
Edward Wolf, M.D., Northwestern University
Case Studies in NIPT
Nicole Teed, Medical Science Liaison, Sequenom, Inc.
Case Study: Clinical Exome Sequencing for the Diagnosis of Neurodegenerative Disorders
Rong Mao, M.D., Associate Professor, Pathology, University of Utah; Medical Director, Molecular Genetics, ARUP Laboratories
Case Study: Clinical Utility of Multiple-Gene Sequencing Panels for Hereditary Cancer Risk Assessment
James M. Ford, M.D., Associate Professor, Medicine & Genetics, Division of Oncology, Stanford University School of Medicine
Case Study: Applying Next-Generation Sequencing for Mutation Detection in Hematologic Malignancies with an Emphasis on Value Added to Patient Care
Jennifer J.D. Morrissette, Ph.D., Clinical Director, Center for Personalized Diagnostics, University of Pennsylvania
Case Study: Applying Next-Generation Sequencing for Rapid Pathogen Detection
Charles Chiu, M.D., Ph.D., Assistant Professor, Laboratory Medicine and Medicine/Infectious Diseases; Director, UCSF-Abbott Viral Diagnostics and Discovery Center; Associate Director, UCSF Clinical Microbiology Laboratory, UCSF School of Medicine
Validation Challenges for Panels and Exomes
Josh Deignan, Ph.D., Associate Director, UCLA Molecular Diagnostics Laboratories, Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA
FDA-Approved Versus LDT-Based NGS Panels: Preanalytical Issues and Validation
Jamie L Platt, Ph.D., Vice President, Genomic Solutions, Molecular Pathology Laboratory Network, Inc.
PANEL DISCUSSION: Analyzing and Comparing Major NGS Instruments
Moderator: Jamie L Platt, Ph.D., Vice President, Genomic Solutions, Molecular Pathology Laboratory Network, Inc.
Panelists to be Announced
Advancing Clinical Outcomes with Targeted Therapies for Patients with Solid Tumors Using the Next-Generation Sequencing Assay
Jeffrey S. Ross, M.D., Medical Director, Foundation Medicine, Inc.
The NGS Cost Equation in Cancer Care: Are We at the Tipping Point?
German Pihan, M.D., Director, Hematopathology Lab, Pathology, Beth Israel Deaconess Medical Center & Harvard Medical School
KEYNOTE PRESENTATION: Common Uses of NGS in the Clinic: Cancer, NIPT and Pediatric Applications
Paul R. Billings, M.D., Ph.D., CMO, Thermo Fisher Scientific
Dietrich A. Stephan, Ph.D., Chairman, Human Genetics, University of Pittsburgh; Associate Director; Population Genetics and Translational Acceleration, Institute for Personalized Medicine of UPMC & University of Pittsburgh Health
Robert C. Green, M.D., MPH, Director, G2P Research Program; Associate Director, Research, Partners Center for Personalized Genetic Medicine, Division of Genetics, of Medicine, Brigham and Women’s Hospital and Harvard Medical School
KEYNOTE PRESENTATION: Cancer Genomics
David Haussler, Ph.D., Distinguished Professor and Director, Center for Biomolecular Science & Engineering, University of California Santa Cruz
Ranking Omics Data to Discover Diagnostic Biomarkers
Corrado Priami, Ph.D., Computer Science, The Microsoft Research - University of Trento Center for Computational and Systems Biology (COSBI)